OYAVAS 25 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oyavas 25 mg/1 ml koncentrat za rastvor za infuziju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - bevacizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 4 ml koncentrata za rastvor za infuziju sadrži: 100 mg bevacizumaba (25 mg/ml)

OYAVAS 25 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oyavas 25 mg/1 ml koncentrat za rastvor za infuziju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - bevacizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 16 ml koncentrata za rastvor za infuziju sadrži: 400 mg bevacizumaba (25 mg/ml)

ALYMSYS 25 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alymsys 25 mg/1 ml koncentrat za rastvor za infuziju

zentiva pharma d.o.o. - bevacizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 1 bočica sa 4 ml koncentrata za rastvor za infuziju sadrži: 100 mg bevacizumaba (25 mg/ml)

ALYMSYS 25 mg/1 mL koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alymsys 25 mg/1 ml koncentrat za rastvor za infuziju

zentiva pharma d.o.o. - bevacizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 1 bočica sa 16 ml koncentrata za rastvor za infuziju sadrži: 400 mg bevacizumaba (25 mg/ml)

AVASTIN 100 mg/4 mL koncentrat otopine za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

avastin 100 mg/4 ml koncentrat otopine za infuziju

roche d.o.o.roche ltd. - bevacizumab - koncentrat otopine za infuziju - 100 mg/4 ml - 4 ml koncentrata za otopinu za infuziju sadrži: 100 mg bevacizumaba (25 mg/ml)

AVASTIN 400 mg/16 mL koncentrat otopine za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

avastin 400 mg/16 ml koncentrat otopine za infuziju

roche d.o.o.roche ltd. - bevacizumab - koncentrat otopine za infuziju - 400 mg/16 ml - 16 ml kocentrata za otopinu za infuziju sadrži: 400 mg bevacizumaba (25 mg/ml)

Ipique Europska Unija - hrvatski - EMA (European Medicines Agency)

ipique

rotterdam biologics b.v. - bevacizumab - mokro makularna degeneracija - ophthalmologicals - treatment of neovascular (wet) age-related macular degeneration (amd).

Lynparza Europska Unija - hrvatski - EMA (European Medicines Agency)

lynparza

astrazeneca ab - olaparib - neoplazme jajnika - antineoplastična sredstva - jajnika cancerlynparza prikazan kao monoterapija za:podržava liječenje odraslih bolesnika s поздними (figo faze iii i iv) u genima brca1/2-mutirani (зародышевой linije i/ili somatskih) brzorezni epitela jajnika, masterbatch cijevi ili primarni перитонеальный rak, koji u odgovor (potpuno ili djelomično) nakon završetka prve linije na bazi platine kemoterapije. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 i 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacijenti moraju prethodno bile tretirane s антрациклина i таксана u (neo)adjuvantne ili метастатический, ako pacijenti nisu prikladni za tih postupaka (vidi odjeljak 5. pacijenti s receptore hormona (h)-pozitivnog raka dojke treba također razvili ili nakon pre-hormonska terapija, ili se smatraju neprikladnim za endokrine terapije. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Lonsurf Europska Unija - hrvatski - EMA (European Medicines Agency)

lonsurf

les laboratoires servier - trifluridine, tipiracil hidroklorid - kolorektalne neoplazme - antineoplastična sredstva - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Teysuno Europska Unija - hrvatski - EMA (European Medicines Agency)

teysuno

nordic group b.v. - тегафур, gimeracil, oteracil - neoplazme želuca - antineoplastična sredstva - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.